TSIDS01: Treatment Disposition and Reasons for Discontinuation from Treatment; Treated Analysis Set (Study GRN163LMYF3001)

	Randomized			
	Dummy Imetelstat (N=176)	Dummy BAT (N=85)	Dummy Crossover Imetelstat (N=15)	Dummy Imetelstat Total (N=191)
Subjects treatment ongoing	63 (35.8%)	26 (30.6%)	6 (40.0%)	69 (36.1%)
Subjects who discontinued the treatment	113 (64.2%)	59 (69.4%)	9 (60.0%)	122 (63.9%)
Reason for discontinuation				
Withdrawal by subject	39 (22.2%)	15 (17.6%)	1 (6.7%)	40 (20.9%)
Progressive disease	29 (16.5%)	18 (21.2%)	2 (13.3%)	31 (16.2%)
Adverse event	11 (6.3%)	6 (7.1%)	3 (20.0%)	14 (7.3%)
Lack of efficacy	14 (8.0%)	8 (9.4%)	0	14 (7.3%)
Physician decision	10 (5.7%)	6 (7.1%)	2 (13.3%)	12 (6.3%)
Death	5 (2.8%)	3 (3.5%)	1 (6.7%)	6 (3.1%)
COVID-19	0	0	0	0
Lost to follow-up	0	0	0	0
Non-compliance with study drug	0	0	0	0
Pregnancy	0	0	0	0
Product quality complaint	0	0	0	0
Protocol violation	0	0	0	0
Study terminated by sponsor	0	0	0	0
Other	4 (2.3%)	3 (3.5%)	0	4 (2.1%)

Key: BAT = Best Available Therapy.
Percentages are calculated with the number of subjects in each treatment group as the denominators.